Biotech Values

[biocqr]

BITI > Finnish biotech Biotie IPO'ing today targeting CNS disorders...currently @ $19


Biotie upsizes IPO as ex-partner UCB decides to cash out
http://www.fiercebiotech.com/story/biotie-upsizes-ipo-ex-partner-ucb-decides-cash-out/2015-06-10

F-1...

http://www.nasdaq.com/markets/ipos/filing.ashx?filingid=10272159

Our Business
We are a biopharmaceutical company primarily focused on developing therapeutics for central nervous system disorders. Our pipeline includes product candidates designed to address unmet medical needs in Parkinson’s disease and related dementia, other neurodegenerative indications and primary sclerosing cholangitis, an orphan fibrotic liver disease. In addition, we have successfully developed a product for alcohol dependence that is being commercialized by Lundbeck and is a source of further potential milestone payments and ongoing royalties.
We are preparing to commence a pivotal Phase 3 clinical trial of our lead product candidate, tozadenant, that we believe could form the basis for its approval in the United States as an adjunctive treatment to levodopa in Parkinson’s. Levodopa, the most widely prescribed treatment for Parkinson’s, loses effectiveness in most patients over time. Parkinson’s patients often experience a reemergence of debilitating symptoms on a daily basis as their levodopa doses wear off. Tozadenant is an oral, selective adenosine A 2a receptor antagonist that aims to address this wearing off effect. In a 420-patient Phase 2b trial, tozadenant displayed clinically important and statistically significant effects across prespecified primary and multiple secondary endpoints at a number of doses. In addition, tozadenant has been found to be generally safe and well tolerated in our ten clinical trials conducted to date.

We also have two additional development-stage product candidates: SYN120 for Parkinson’s disease dementia and Alzheimer’s disease; and BTT1023 for primary sclerosing cholangitis, an orphan fibrotic liver disease. In addition, under our license and commercialization agreement with H. Lundbeck A/S, or Lundbeck, for Selincro, our product for alcohol dependence, we have received €22.0 million in upfront and milestone payments to date and are eligible to receive additional regulatory and commercial milestone payments and ongoing royalties.